跳到正文
原文
Medical Xpress·· 5 小时前AI 评分31

One Health合作研究揭示利什曼病药物耐受相关基因靶点

One Health collaboration leads to potential targets against leishmaniasis, a parasitic disease

AI 导读

德州理工大学与德州理工健康科学中心通过One Health创新研究所种子基金开展合作,利用生物信息学分析比较药物敏感型与持久型利什曼原虫,发现六个与药物耐受相关的基因——三个下调以阻断药物进入,三个上调以将药物泵出。持久态是由环境压力诱导的可逆暂态,可能发展为永久性基因突变耐药,靶向持久态可避免完全耐药的发生。

正文
One health collaboration leads to new discoveries in leishmaniasis research
Eyson Quiceno shows a Leishmania parasite under a microscope. Credit: Texas Tech University Health Sciences Center

Leishmania parasites cause leishmaniasis. The disease is spread through the bite of an infected sand fly. While in the bloodstream, parasites invade host cells where they live and multiply.

According to the Pan American Health Organization, leishmaniasis is among the top 10 neglected tropical diseases, affecting an estimated 12 million people worldwide. There are three main types of leishmaniases: visceral (affecting internal organs and almost always lethal without treatment), cutaneous (causing skin ulcers) and mucocutaneous (affecting the mouth, nose and throat). Cutaneous leishmaniasis is the most common form of the disease. Visceral leishmaniasis is the most life-threatening, ranking second only to malaria as the most fatal of parasitic infections.

In the United States, the number of new leishmaniasis cases is rising. The Centers for Disease Control and Prevention reported that most human cases occur in Texas. Driving factors behind the increase include climate changes, which expand the sand fly's habitat, plus population growth and more international travel, which increase the chance of people encountering the fly.

Through support from the Institute for One Health Innovation, researchers from Texas Tech University Health Sciences Center and Texas Tech University are bringing together their expertise to investigate leishmaniasis, a parasitic disease that presents significant challenges to human health. With no approved human vaccine and growing concerns about drug resistance and treatment persistence, the team is working to identify new potential targets to combat the disease. Credit: Texas Tech University Health Sciences Center

Limited treatments spur collaborative research

There are currently no licensed or approved vaccines to prevent human leishmaniasis. Treatment is limited, and the drugs used carry a high risk of toxicity. Medication also fails frequently due to drug resistance and persistence. The National Institutes of Health (NIH) reported that finding new ways to treat leishmaniasis has been difficult.

Zemfira Karamysheva, Ph.D., an associate professor at the Texas Tech University Health Sciences Center (TTUHSC) School of Medicine Department of Cell Biology and Biochemistry and a faculty member in the Graduate School of Biomedical Sciences, has been researching the Leishmania parasite for years. Along with people, many animals such as horses, dogs, cats, rodents, opossums and armadillos serve as reservoir hosts of leishmaniasis. Karamysheva said the spread of this zoonotic disease—one that impacts people and animals—is of great concern in Texas and other states.

Studying leishmaniasis aligns with the mission of the Institute for One Health Innovation (IOHI), a collaboration among Texas Tech University System institutions. One Health is a term used to recognize that human, animal and environmental health can be linked. It promotes cross-disciplinary teamwork among experts in human, animal and environmental health plus other relevant disciplines to solve complex health issues, such as zoonotic diseases.

Karamysheva teamed up with Caleb Phillips, Ph.D., an associate professor with Texas Tech University's (TTU) Department of Biological Sciences. Phillips' research includes studying how microbiomes relate to health in wildlife and people. Together, they received one of the first seed grants through the IOHI to study the mechanisms of persistence in Leishmania, which frequently lead to infection relapses.

One health collaboration leads to new discoveries in leishmaniasis research
Leishmania parasite viewed with a microscope. Credit: Texas Tech University Health Sciences Center

Bioinformatics brings labs and students together

"He's a great partner; I'm really happy," Karamysheva said. "He has two Ph.D. students who helped to perform bioinformatics analysis."

Bioinformatics analysis combines computer science with biology to better understand large sets of biological data and pathways involved on a whole-genome scale.

"In my lab, we have Ph.D. students who can perform bioinformatics analysis, but the Phillips lab specializes in it," Karamysheva said. "Students from my lab learned a great deal from the Phillips lab students about advanced bioinformatics tools, making it a truly valuable collaboration."

Phillips agreed. He said the project built a strong sense of teamwork.

"This not only helped build a scientific collaboration between faculty but also among the students in respective labs," Phillips said. "This led to technical training that would otherwise not have occurred."

Six genes linked to drug tolerance

The team used bioinformatics to analyze differences between drug-sensitive Leishmania parasites and those considered persisters. Persisters are a small subpopulation of dormant, slow-growing cells that survive high drug concentrations or environmental stress without exhibiting genetic resistance. The team discovered that persisters exhibit distinct drug response profiles compared to parental parasites by rapidly implementing a highly conserved, coordinated survival reprogramming.

"Among many unique changes present in persisters, we found six very interesting genes that could contribute to increased drug tolerance," Karamysheva said. "Three genes are turned down to block drug entry, and three are turned up to pump the drug out."

The discovery is an important step in understanding persistence.

"What distinguishes persistence from drug resistance is that persistence is a temporary state," Karamysheva said. "Once a drug is gone, cells become susceptible again and multiply, which causes infections to return."

Karamysheva explained that persistence can lead to full drug resistance.

"Resistance is a permanent change caused by acquiring gene mutations," Karamysheva said. "Persistence serves as a stepping stone for the establishment of drug resistance."

Targeting persistence before resistance takes hold

Targeting persistence could avoid the development of drug resistance. However, while much is known about drug resistance, Karamysheva said persistence is poorly investigated. She explained that persistence exists in many diseases, including cancer.

"Persisters are so understudied because it's really difficult to isolate them," Karamysheva said. "This grant [IOHI seed grant] allowed us to establish a new model to study persistence."

Published in the October issue of PLOS Pathogens, the team's article "Active transcriptome remodeling underlies antimony-induced drug tolerance in persister-like Leishmania parasites" detailed how the parasites form persisters to survive drug treatment.

Lead author Eyson Quiceno, a medical technician in Karamysheva's lab at the time, stated, "By establishing the model to study persistence in this protozoan parasite, we could define the survival mechanism of Leishmania when facing drug pressure, while also highlighting novel molecular vulnerabilities within the persister population, offering promising therapeutic targets to intercept the transition to resistance and ultimately prevent clinical relapse."

"It is possible that this research, which is based on Karamysheva's ideas, will lead to new and effective treatments," Phillips said.

Publication details

Eyson Quiceno et al., Active transcriptome remodeling underlies antimony-induced drug tolerance in persister-like Leishmania parasites, PLOS Pathogens (2026). DOI: 10.1371/journal.ppat.1014682

Journal information: PLoS Pathogens

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: One Health collaboration leads to potential targets against leishmaniasis, a parasitic disease (2026, November 19) retrieved 19 November 2026 from https://medicalxpress.com/news/2026-11-health-collaboration-potential-leishmaniasis-parasitic.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com